TY - JOUR
T1 - Nerve conduction velocity in CMT1A: what else can we tell?
AU - Manganelli, F
AU - Pisciotta, C
AU - Reilly, Mm
AU - Tozza, S
AU - Schenone, A
AU - Fabrizi, Gm
AU - Cavallaro, T
AU - Vita, G
AU - Padua, Luca
AU - Gemignani, F
AU - Laurà, M
AU - Hughes, Ra
AU - Solari, A
AU - Pareyson, D
AU - Santoro, L
AU - TRIAAL, CMT
AU - Group, CMT TRAUK
PY - 2016
Y1 - 2016
N2 - BACKGROUND AND PURPOSE:\r\n\r\nCharcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A.\r\nMETHODS:\r\n\r\nBaseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot-Marie-Tooth Examination Score (CMTES).\r\nRESULTS:\r\n\r\nNCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES.\r\nCONCLUSIONS:\r\n\r\nThis is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.
AB - BACKGROUND AND PURPOSE:\r\n\r\nCharcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of the present study was to analyze the large amount of electrophysiological data collected in the ascorbic acid trial in Italy and the UK (CMT-TRIAAL/CMT-TRAUK) and to use these data to gain insights into the pathophysiology of NCV in CMT1A.\r\nMETHODS:\r\n\r\nBaseline electrophysiological data from 271 patients were analysed. Electrophysiological recordings were taken from the motor ulnar, median and peroneal nerves and the sensory ulnar nerve. Distal motor latency (DML), motor (MNCV) and sensory (SNCV) nerve conduction velocity, and amplitudes of CMAPs and sensory action potentials were assessed. Electrophysiological findings were correlated with age of patients at examination and the Charcot-Marie-Tooth Examination Score (CMTES).\r\nRESULTS:\r\n\r\nNCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with age of the patients, whereas CMAP amplitudes worsened with age and also correlated with CMTES.\r\nCONCLUSIONS:\r\n\r\nThis is the largest sample of electrophysiological data obtained so far from CMT1A patients. Axonal degeneration as assessed by means of CMAP amplitude reflected clinical impairment and was consistent with a slowly progressive length-dependent neuropathy. All patients typically had markedly slowed NCV that did, however, slightly increase with age of the patients. The improvement of NCV might depend on myelin thickness remodelling that occurs during the adult life of CMT1A patients.
KW - CMT-TRIAAL/CMT-TRAUK
KW - CMT1A
KW - Charcot−Marie−Tooth disease
KW - hereditary neuropathies
KW - nerve conduction velocity
KW - CMT-TRIAAL/CMT-TRAUK
KW - CMT1A
KW - Charcot−Marie−Tooth disease
KW - hereditary neuropathies
KW - nerve conduction velocity
UR - https://publicatt.unicatt.it/handle/10807/88258
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84987752669&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84987752669&origin=inward
U2 - 10.1111/ene.13079
DO - 10.1111/ene.13079
M3 - Article
SN - 1468-1331
VL - 23
SP - 1566
EP - 1571
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 10
ER -